A Case of Ticagrelor-Induced Sinus Pause.
Nicholas T Pavlatos1, Aangi Shah1, Muhammad Khan2
1Department of Internal Medicine, University of Louisville Hospital, Louisville, USA.
Ticagrelor, an antiplatelet drug, can cause sinus pauses by inhibiting adenosine uptake. This case highlights prolonged sinus pauses occurring hours after ticagrelor initiation post-percutaneous coronary intervention.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ticagrelor is a widely used oral antiplatelet agent post-percutaneous coronary intervention (PCI).
- Bradyarrhythmias, particularly sinus pauses, have been associated with ticagrelor use.
- The mechanism is hypothesized to involve ticagrelor's inhibition of human equilibrative nucleoside transporter 1 (hENT1), affecting adenosine uptake.
Observation:
- A 58-year-old male presented with prolonged sinus pauses.
- These events occurred 38 hours after initiating ticagrelor.
- The patient had undergone PCI for ST-elevation myocardial infarction.
Findings:
- The case illustrates a delayed onset of ticagrelor-induced bradyarrhythmia.
- This finding supports the link between ticagrelor, hENT1 inhibition, and adenosine levels.
- Prolonged sinus pauses represent a significant adverse cardiac event.
Implications:
- Clinicians should be vigilant for bradyarrhythmias in patients taking ticagrelor, even hours after initiation.
- Understanding the adenosine-related mechanism is crucial for managing ticagrelor-associated cardiac events.
- Further research may explore monitoring adenosine levels or alternative antiplatelet strategies.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Acute Coronary Syndrome III: Diagnostic Studies
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias


